Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

(2012) Jean-Philippe Jacquin et al.   BREAST CANCER RESEARCH AND TREATMENT

Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

(2012) Lawrence N. Shulman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

(2010) Miguel Martín et al.   NEW ENGLAND JOURNAL OF MEDICINE

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

(2009) Stephen Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

(2008) Lori J. Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

(2008) M. Martin et al.   JNCI-Journal of the National Cancer Institute

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

(2008) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials

(2007) Michele De Laurentiis et al.   JOURNAL OF CLINICAL ONCOLOGY